{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT04557150","nct_id":"NCT04557150","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04557150. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive forimtamig as intravenous (IV) infusion and/or subcutaneous (SC) injection in a step-up dosing fashion.","label":"Part I: Dose Escalation","type":"EXPERIMENTAL"},{"description":"Dose Expansion cohorts with IV and/or SC administration, respectively, will be initiated at the Recommended Phase 2 Doses (RP2Ds) determined in Part I: Dose Escalation phase.","label":"Part II: Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-03-17","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":225,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Forimtamig","otherNames":["RO7425781"],"type":"DRUG"}],"last_update":"2026-04-13","lead_sponsor":"Hoffmann-La Roche","official_title":"An Open-Label, Multicenter, Phase I Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig (RO7425781) in Participants With Relapsed or Refractory Multiple Myeloma","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2026-03-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants with Adverse Events (AEs)","timeFrame":"Up to 104 weeks"},{"measure":"Percentage of Participants with Dose Limiting Toxicities (DLTs)","timeFrame":"Cycle 1 Day 1 up to Cycle 1 Day 35"}],"references":[{"citation":"Kraft TE, Marrer-Berger E, Belli S, Haegel H, Schneider A, Giusti AM, Bscheider M, Jacob W, Weisser M, Blanco L, Frances N, Rossmann E, Steiner G, Azpiroz AZ, Paiva B, Martinet L, Fauti T. Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma. Clin Pharmacol Ther. 2026 Sep;120(3):745-752. doi: 10.1002/cpt.70366. Epub 2026 Jun 17.","pmid":"42310437","type":"DERIVED"},{"citation":"Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, Gottwald S, Rae R, Lechner S, Bayer C, Dekempe Q, Osl F, Carrie N, Kassem S, Lorenz S, Christopeit T, Carpy A, Bujotzek A, Broske AM, Dekhtiarenko I, Attig J, Kunz L, Cremasco F, Adelfio R, Fertig G, Dengl S, Gassner C, Bormann F, Kirstenpfad C, Kraft T, Diggelmann S, Knobloch M, Hage C, Feddersen R, Heidkamp G, Poschinger T, Mayoux M, Bernasconi L, Prosper F, Dumontet C, Martinet L, Leclair S, Xu W, Paiva B, Klein C, Umana P. Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma. Blood. 2025 Jan 9;145(2):202-219. doi: 10.1182/blood.2024025987.","pmid":"39476124","type":"DERIVED"}],"start_date":{"date":"2020-11-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)","url":"https://clinicaltrials.gov/study/NCT04557150"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04557150"}